Skip to main content

Table 3 Risk factors for unfavourable treatment outcomes among the MDR-TB patients received non-MDR-TB treatment

From: Treatment quality and outcome for multidrug-resistant tuberculosis patients in four regions of China: a cohort study

Factors

Patients with non-MDR-TB treatment

Odds ratio (95% CI)

Adjusted odds ratio (95% CI) a

Favourable outcomes (n = 13)

Unfavourable outcomes (n = 24)

Age (mean±SD)

43.2 ± 19.8

55.1 ± 14.1

0.96 (0.91–1.00)

 

Male

12 (92.3)

22 (91.7)

1.09 (0.09–13.3)

 

Study sites in

 Western

10 (76.9)

20 (83.3)

1

 

 Eastern

3 (23.1)

4 (16.7)

1.50 (0.28–8.04)

 

Body mass index (mean±SD)

21.4 ± 2.2

20.1 ± 2.2

1.33 (0.95–1.86)

1.41 (0.97–2.06)

Education

 Primary school or below

4 (30.8)

20 (83.3)

1

1

 Junior high school or above

9 (69.2)

4 (16.7)

11.3 (2.29–55.4)

9.78 (1.77–54.0)

Married

8 (61.5)

11 (45.8)

1.89 (0.48–7.49)

1.69 (0.32–8.93)

Health insurance

13 (100.0)

23 (95.8)

  

Haemoptysis

3 (23.1)

8 (33.3)

0.60 (0.13–2.81)

0.53 (0.10–2.84)

Tuberculosis treatment history

4 (30.8)

14 (58.3)

0.32 (0.08–1.33)

0.15 (0.02–1.05)

Pulmonary cavities

7 (53.8)

9 (37.5)

1.94 (0.49–7.64)

1.86 (0.37–9.19)

DST pattern

 MDR

7 (53.8)

9 (37.5)

1

1

 Pre-XDR and XDR

6 (46.2)

15 (62.5)

0.51 (0.13–2.02)

0.64 (0.14–2.84)

Strain family (n = 33)

 Non-Beijing family

2 (16.7)

2 (9.5)

1

1

 Beijing family

10 (83.3)

19 (90.5)

0.53 (0.06–4.32)

0.90 (0.08–10.2)

Total delay (days)

  ≤ 90.0

9 (69.2)

12 (50.0)

1

1

  > 90.0

4 (30.8)

12 (50.0)

0.44 (0.11–1.85)

0.36 (0.05–2.39)

  1. DNA was failure to extract from six Mycobacterium tuberculosis isolates. Two patients were once reported as treatment success but were lost at the last yearly follow-up, thus excluded from the analysis. MDR Multidrug-resistant, SD Standard deviation, DST Drug susceptibility testing, XDR Extensively drug-resistant
  2. aAdjusted by age, gender and study sites